Satoshi Ano, Norihiro Kikuchi, Shinichiro Okauchi, Takeshi Numata, Ryota Nakamura, Toshihiro Shiozawa, Hiroko Watanabe, Tomohiro Tamura, Kunihiko Miyazaki, Shigen Hayashi, Takaaki Yamashita, Koichi Kurishima, Masaharu Inagaki, Takayuki Kaburagi, Takeo Endo, Hiroaki Satoh, Nobuyuki Hizawa
BACKGROUND/AIM: Atezolizumab, an anti-PD-L1 antibody, has been increasingly administered in combination with chemotherapy to patients with small cell lung cancer (SCLC). This study aimed to determine how patients with extensive disease (ED) -SCLC responded to atezolizumab with chemotherapy and found factors affecting long-term response and survival. PATIENTS AND METHODS: This study focused on patients with SCLC who were treated with a combination of atezolizumab and chemotherapy in Japan between 2019 and 2023...
June 2024: Anticancer Research